Results 51 to 60 of about 33,915 (216)

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Low-Cost Portable Light Therapy for Alzheimer's Patients [PDF]

, 2019
This paper provides an overview of the information and research conducted that ushered the creation and innovation of a low-cost portable light therapy device to help treat Alzheimer’s patients.
Arasu, Melghi, Zoghi, Ben, Zoghi, Sara
core   +1 more source

The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion‐Tensor‐Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. This number is projected to increase to 13.8 million in the United States by 2060, leading to increased expenditures for healthcare, long‐term care and hospice services. Consequently,
Valentina Zecca, Gianmauro Palombelli, Nicola Vanacore, Rossella Canese   +3 more
wiley   +1 more source

Silodosin oral films: Development, physico-mechanical properties and in vitro dissolution studies in simulated saliva [PDF]

, 2019
Sublingual film dosage forms for drugs used for fast symptomatic treatment have promise because they allow a rapid onset of action. The aim of this study was to prepare films of silodosin intended for sublingual administration for the symptomatic ...
Adair, Alhayali, Allam, Alonzo, Boateng, Brady, Brouwers, Campisi, Chapple, Curatolo, De Caro, El-Setouhy, ElMeshad, Gao, Garsuch, Gittings, Guo, Hanif, Hobbs, Huang, Humphrey, Jug, Kalia, Kapoor, Kim, Koland, Korhonen, Li, Liew, Madhav, Mashru, Matsubara, Miller-Chou, Montorsi, Nagy, Patel, Prabhu, Prasad, Preis, Preis, Preis, Radebaugh, Repka, Rossi, Runja, Sharma, Singh, Singh, Singh, Singh, Slavkova, Tanno, Vila, Visser, Vuddanda, Vuddanda, Yang, Zhang   +57 more
core   +2 more sources

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]

, 2015
In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani, Alessandro eStefani, Atticus H Hainsworth, Claudio eLiguori, Enrica eOlivola, Giacoma eAngileri, Mariangela ePierantozzi, Salvatore eGalati, Valentina eSaviozzi, Vincenza eD’Angelo   +9 more
core   +3 more sources

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Neuroprotective effects of donepezil against Aβ25-35-induced neurotoxicity

European Journal of Medical Research, 2022
Purpose The purpose of this study was to investigate the neuroprotective effect of donepezil against β-amyloid25-35 (Aβ25-35)-induced neurotoxicity and the possible mechanism. Methods PC12 cells were conventionally cultured. Serial concentrations of Aβ25-
Bu-Lang Gao, Ning-Ning Che, Xue Li, Chun-Feng Ren   +3 more
doaj   +1 more source

Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]

, 2019
Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core  

Motor cortex excitability changes in mild Alzheimer's disease are reversed by donepezil. [PDF]

, 2014
peer reviewedBACKGROUND: Recent neuroimaging studies in humans support the clinical observations that the motor cortex is affected early in the course of Alzheimer's disease (AD).
BALLA, Christina, MAERTENS DE NOORDHOUT, Alain, PEPIN, Jean-Louis   +2 more
core   +1 more source